Glucagon-like peptide 1 receptor (GLP1R) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (GLP1R + HMGCR)

The target 'GLP-1 receptor + HMG-CoA reductase' refers to a therapeutic strategy involving the simultaneous modulation of the Glucagon-like peptide 1 receptor (GLP1R) and the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). GLP1R is a class B G protein-coupled receptor that plays a critical role in glucose homeostasis by stimulating insulin secretion and suppressing glucagon release in response to food intake [1][2]. HMGCR is the rate-limiting enzyme in the mevalonate pathway, responsible for the endogenous synthesis of cholesterol in the liver [3][4]. While these are distinct biological entities, they are frequently co-targeted in clinical practice to manage the complex interplay of hyperglycemia, obesity, and dyslipidemia in patients with type 2 diabetes and metabolic syndrome [5]. GLP-1 receptor agonists, such as semaglutide, provide glycemic control and weight reduction, while HMG-CoA reductase inhibitors, known as statins, are the gold standard for lowering LDL cholesterol and reducing cardiovascular events [4][6]. Combining these therapies addresses multiple risk factors for atherosclerotic cardiovascular disease, which is the leading cause of morbidity in diabetic populations [5]. This dual-target approach is supported by major clinical guidelines to optimize cardiometabolic health [5].

Other names

GLP1RHMGCRGLP-1RHMG-CoA Reductase3-hydroxy-3-methylglutaryl-CoA reductaseHMG-CoA reductase

GLP-1 receptor agonists bind to the GLP-1 receptor (GLP1R), a G protein-coupled receptor, to stimulate glucose-dependent insulin secretion from pancreatic beta cells and suppress glucagon secretion from alpha cells [1][6]. They also delay gastric emptying and act on the hypothalamus to increase satiety [2]. HMG-CoA reductase inhibitors (statins) competitively inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) enzyme, the rate-limiting step in the mevalonate pathway [4]. This inhibition reduces hepatic cholesterol synthesis, leading to the upregulation of LDL receptors on the surface of hepatocytes, which enhances the clearance of low-density lipoprotein (LDL) from the bloodstream [3][4].